Literature DB >> 22648114

Long-term postoperative outcomes of hypersplenism: laparoscopic versus open splenectomy secondary to liver cirrhosis.

Jin Zhou1, Zhong Wu, Prasoon Pankaj, Bing Peng.   

Abstract

BACKGROUND: Hypersplenism is a common clinical manifestation in patients with liver cirrhosis. For treatment, surgeons can choose between two options: open splenectomy (OS) or laparoscopic splenectomy (LS). Although splenectomy has wide exposure and acceptance as a remedy for the patients with hypersplenism secondary to liver cirrhosis, the data are sparse with regard to its long-term outcomes, including hematologic response and liver function after the surgery. This study aimed to determine the long-term effect of OS versus LS for cirrhotic patients with hypersplenism.
METHODS: Between September 2003 and June 2011, the study enrolled 63 consecutive patients with hypersplenism secondary to liver cirrhosis who were treated with LS (n = 34) or OS (n = 29). The hematologic parameters and liver function in both groups were evaluated before and after splenectomy, and a comparative study of the long-term follow-up period was conducted.
RESULTS: Postoperatively, 100% of the patients in both groups had a complete response in terms of platelet and leukocyte counts. No changes in liver function were noted. The LS group benefited from less intraoperative blood loss and a shorter postoperative hospital stay than the OS group experienced. The mean follow-up period was 25 months. To date, no death has been reported in either group. All the patients showed complete or partial hematologic response to splenectomy and exhibited improvement in liver function. None of the parameters differed significantly between the two groups. Portal or splenic vein thromboses were detected in three patients (2 in OS and 1 in LS), whereas esophageal variceal bleeding occurred for one patient in the LS group and one patient in the OS group.
CONCLUSION: This study investigated patients with hypersplenism secondary to liver cirrhosis. The findings showed that LS can be considered a well-disposed surgical procedure with good surgical outcomes compared with OS.

Entities:  

Mesh:

Year:  2012        PMID: 22648114     DOI: 10.1007/s00464-012-2349-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  39 in total

Review 1.  Haemostatic abnormalities in patients with liver disease.

Authors:  Ton Lisman; Frank W G Leebeek; Philip G de Groot
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

2.  Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis.

Authors:  Paul H Hayashi; Carlos Mehia; H Joachim Reimers; Harvey S Solomon; Bruce R Bacon
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

3.  Significance of laparoscopic splenectomy in patients with hypersplenism.

Authors:  Yuji Watanabe; Atsushi Horiuchi; Motohira Yoshida; Yuji Yamamoto; Hiroki Sugishita; Teru Kumagi; Yoichi Hiasa; Kanji Kawachi
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

4.  Recent role of splenectomy in chronic hepatic disorders.

Authors:  Toru Ikegami; Mitsuo Shimada; Satoru Imura
Journal:  Hepatol Res       Date:  2008-08-05       Impact factor: 4.288

5.  Effect of splenectomy on CCl4-induced liver fibrosis in rats.

Authors:  D Chen; W Liu; E Leng; B Wu
Journal:  Chin Med J (Engl)       Date:  1998-09       Impact factor: 2.628

6.  Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients.

Authors:  Gisèle N'Kontchou; Olivier Seror; Valérie Bourcier; Djamila Mohand; Yves Ajavon; Laurent Castera; Véronique Grando-Lemaire; Nathalie Ganne-Carrie; Nicolas Sellier; Jean-Claude Trinchet; Michel Beaugrand
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

7.  Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism.

Authors:  Hirofumi Kawanaka; Tomohiko Akahoshi; Nao Kinjo; Kozou Konishi; Daisuke Yoshida; Go Anegawa; Shohei Yamaguchi; Hideo Uehara; Naotaka Hashimoto; Norifumi Tsutsumi; Morimasa Tomikawa; Yoshihiko Maehara
Journal:  Ann Surg       Date:  2010-01       Impact factor: 12.969

8.  Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia.

Authors:  Daisuke Morihara; Masahiro Kobayashi; Kenji Ikeda; Yusuke Kawamura; Hiromi Saneto; Hiromi Yatuji; Tetuya Hosaka; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Fumitaka Suzuki; Hiromitu Kumada
Journal:  Hepatol Res       Date:  2009-01-16       Impact factor: 4.288

9.  Management of gastric variceal haemorrhage.

Authors:  J D Greig; O J Garden; J R Anderson; D C Carter
Journal:  Br J Surg       Date:  1990-03       Impact factor: 6.939

10.  Effect of laparoscopic splenectomy on portal hypertensive gastropathy in cirrhotic patients with portal hypertension.

Authors:  Go Anegawa; Hirofumi Kawanaka; Hideo Uehara; Tomohiko Akahoshi; Kozo Konishi; Daisuke Yoshida; Nao Kinjo; Naotaka Hashimoto; Morimasa Tomikawa; Makoto Hashizume; Yoshihiko Maehara
Journal:  J Gastroenterol Hepatol       Date:  2009-09       Impact factor: 4.029

View more
  14 in total

Review 1.  Laparoscopic splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension.

Authors:  Xiao-Li Zhan; Yun Ji; Yue-Dong Wang
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  Laparoscopic splenectomy is a better surgical approach for spleen-relevant disorders: a comprehensive meta-analysis based on 15-year literatures.

Authors:  Ji Cheng; Kaixiong Tao; Peiwu Yu
Journal:  Surg Endosc       Date:  2016-02-19       Impact factor: 4.584

3.  Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis.

Authors:  Yanyan Wu; Hongyu Li; Tiansong Zhang; Zhaohui Bai; Xiangbo Xu; Giovanni Battista Levi Sandri; Le Wang; Xingshun Qi
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

4.  Efficacy and safety of laparoscopic splenectomy in thrombocytopenia secondary to systemic lupus erythematosus.

Authors:  Jin Zhou; Zhong Wu; Zongguang Zhou; Zhiqiang Wang; Yi Liu; Xiang-Yang Huang; Bing Peng
Journal:  Clin Rheumatol       Date:  2013-04-03       Impact factor: 2.980

Review 5.  Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review.

Authors:  Demetrios Moris; Nikoletta Dimitriou; John Griniatsos
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

6.  Transjugular intrahepatic portosystemic shunt (TIPS) versus laparoscopic splenectomy (LS) plus preoperative endoscopic varices ligation (EVL) in the treatment of recurrent variceal bleeding.

Authors:  Jin Zhou; Zhong Wu; Junchao Wu; Xin Wang; Yongbin Li; Mingjun Wang; Zhengguo Yang; Bing Peng; Zongguang Zhou
Journal:  Surg Endosc       Date:  2013-02-08       Impact factor: 4.584

7.  Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.

Authors:  Zhong Wu; Jin Zhou; Xin Wang; Yong-Bin Li; Ting Niu; Bing Peng
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

8.  Laparoscopic splenectomy plus preoperative endoscopic variceal ligation versus splenectomy with pericardial devascularization (Hassab's operation) for control of severe varices due to portal hypertension.

Authors:  Jin Zhou; Zhong Wu; Junchao Wu; Bing Peng; Xin Wang; Mingjun Wang
Journal:  Surg Endosc       Date:  2013-07-12       Impact factor: 4.584

9.  Risk Factors of Portal Vein Thrombosis after Devascularization Treatment in Patients with Liver Cirrhosis: A Nested Case-Control Study.

Authors:  Shenxin Lu; Guohua Hu; Shiyao Chen; Jian Wang
Journal:  Biomed Res Int       Date:  2020-08-27       Impact factor: 3.411

10.  Laparoscopic splenic artery ligation for hypersplenism in cirrhosis: A case series.

Authors:  Hirdaya H Nag; Sandip Chandrasekar; John M Manipadum; Bettageri G Vageesh
Journal:  J Minim Access Surg       Date:  2016 Oct-Dec       Impact factor: 1.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.